• RNA Pol II Inhibition Triggers Apoptosis Beyond Loss of Tran

  2026-05-04

  Harper et al. (2025) challenge the prevailing model that cell death upon RNA polymerase II (RNA Pol II) inhibition is due to loss of transcription. Instead, they demonstrate that the loss of the hypophosphorylated RNA Pol IIA isoform activates an apoptotic signaling pathway, providing new mechanistic insight into regulated cell death. This work has important implications for cancer research and the development of targeted therapies.

• Roscovitine (Seliciclib): A Paradigm Shift in CDK-Driven Onc

  2026-05-04

  This thought-leadership article explores Roscovitine (Seliciclib, CYC202) as a transformative tool in translational cancer research, blending mechanistic insight with strategic guidance. We synthesize current evidence on cell cycle control, in vivo efficacy, and data-driven library design, providing actionable recommendations for researchers. By integrating recent cheminformatics advances and APExBIO’s trusted manufacturing, we chart a forward-looking path for CDK-targeted therapeutics.

• Ribonuclease R (20 U/μL): Elevating Circular RNA Enrichment

  2026-05-03

  Ribonuclease R (20 U/μL) from APExBIO enables precise, selective degradation of linear RNA, streamlining robust circular RNA enrichment and structure-function investigations. Discover optimized workflows and troubleshooting strategies that unlock new insights into inflammation and DNA damage pathways.

• Fluorescent RNA Probes: Strategic Leverage for Translational

  2026-05-02

  This thought-leadership article explores the mechanistic, strategic, and translational dimensions of fluorescent RNA probe synthesis using the HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit. Framed by recent advances in targeted mRNA delivery and gene expression control, we outline how innovations in Cy3 RNA labeling are transforming experimental design for in situ hybridization, Northern blotting, and next-generation therapeutic research. Drawing on leading peer-reviewed studies, comparative vendor analysis, and real-world laboratory protocols, we provide actionable guidance for translational researchers seeking robust, reproducible, and customizable fluorescent RNA probe workflows.

• Methylprednisolone Sodium Succinate in Immunology Workflows

  2026-05-01

  Methylprednisolone Sodium Succinate streamlines inflammation and immunology assays by offering potent, predictable immunomodulation and apoptosis induction in tumor cell models. This guide delivers evidence-based protocols, troubleshooting insights, and comparative applications, empowering researchers to achieve reproducible, high-quality results in diverse experimental contexts.

• Angiotensin (1-7): Optimizing Bench Protocols for Translatio

  2026-05-01

  Angiotensin (1-7) (Asp-Arg-Val-Tyr-Ile-His-Pro) empowers advanced research on anti-fibrotic, anti-inflammatory, and metabolic pathways, offering high reproducibility and cross-system application. This guide delivers actionable workflows, protocol benchmarks, and troubleshooting tips to maximize data reliability—anchored in recent findings and APExBIO’s high-purity peptide resource.

• TG003 Cdc2-like Kinase Inhibitor: Precision Splicing, Platin

  2026-04-30

  Explore the unique advantages of TG003, a potent Cdc2-like kinase inhibitor, for advanced alternative splicing modulation and platinum resistance research. This article delivers exclusive insights on assay design, translational relevance, and clinical implications.

• Partial BACE1 Inhibition Lowers Amyloid-β Without Synaptic L

  2026-04-30

  Satir et al. (2020) demonstrate that moderate inhibition of BACE1, achieving less than 50% reduction in amyloid-β (Aβ) production, does not impair synaptic transmission in primary neuronal cultures. This work clarifies a therapeutic window for BACE inhibitor dosing in Alzheimer's disease research, supporting the strategic use of partial BACE1 inhibition.

• HyperScribe T7 High Yield Cy3 RNA Labeling Kit: Enabling Nex

  2026-04-29

  Discover how the HyperScribe T7 High Yield Cy3 RNA Labeling Kit empowers researchers to generate high-yield, optimally labeled fluorescent RNA probes for advanced in situ applications. This article reveals the underlying scientific rationale, practical assay optimization, and translational opportunities unique to APExBIO’s Cy3 RNA labeling kit.

• MALAT1 Modulates PCT in Sepsis via miR-125b/STAT3: Mechanist

  2026-04-29

  This study elucidates how the long noncoding RNA MALAT1 regulates procalcitonin (PCT) expression in sepsis through the miR-125b/STAT3 axis, revealing a new layer of post-transcriptional control in sepsis pathogenesis. The findings highlight potential biomarkers and therapeutic targets, while advanced RNA labeling methods facilitate such mechanistic explorations.

• Organic Cation Transporter Response to Xenobiotics in Aedes

  2026-04-28

  This study characterizes how Aedes aegypti mosquitoes physiologically and molecularly respond to injected xenobiotic dyes, including Olsalazine. By quantifying dye clearance and transporter gene expression, the research identifies limited transcriptional changes but significant physiological impacts, informing future mosquito control strategies via xenobiotic transport pathways.

• Hepatic sEH–Nrf2 Axis Regulates Osteoclastogenesis in Osteop

  2026-04-28

  This study uncovers a mechanistic liver-bone axis in osteoporosis, demonstrating that hepatic soluble epoxide hydrolase (sEH) promotes osteoclast differentiation by suppressing the Nrf2 signaling pathway. These findings clarify redox imbalance mechanisms in bone homeostasis and suggest new molecular targets for translational bone research.

• Ginsenoside Rg1: Triterpene Saponin Workflows for Neuroprote

  2026-04-27

  Ginsenoside Rg1 from APExBIO empowers highly controlled neuroimmune modulation in advanced neuroprotection research. Learn how to translate recent mechanistic breakthroughs into robust, reproducible workflows—complete with protocol optimization, troubleshooting, and actionable insights for apoptosis and inflammation modelers.

• MK 0893: Glucagon Receptor Antagonist for Robust Diabetes Mo

  2026-04-27

  MK 0893, a potent and selective glucagon receptor antagonist, empowers researchers to precisely inhibit GCGR signaling in both cellular and in vivo models of type 2 diabetes. With validated nanomolar potency and broad translational evidence, this APExBIO reagent enables reproducible, mechanism-driven experiments and accelerates discovery of metabolic and oncological therapies.

• Coptisine Modulates SIRT1 Ubiquitination to Alleviate PCOS P

  2026-04-26

  This study establishes the mechanistic link between the traditional herbal formulation Jiao-tai-wan (JTW) and improved ovarian function in DHEA-induced PCOS. The authors identify coptisine as a bioactive component that suppresses SIRT1 ubiquitination, limiting mitochondrial cholesterol import and aberrant steroidogenesis, thus providing a detailed molecular rationale for targeting SIRT1 in PCOS models.

14530 records 1/969 page Next 12345 下5页 Last page